Novo Nordisk transfers Parkinson's therapy development to startup Cellular Intelligence

Novo Nordisk transferred the experimental cell therapy STEM-PD to the startup Cellular Intelligence. The therapy, which Novo itself froze in October, is designed to treat Parkinson's disease.

What happened in the deal

Novo Nordisk announced a partnership with Cellular Intelligence, a startup backed by the Chan Zuckerberg Initiative and other investors. The company transferred to them STEM-PD — an experimental stem cell-based therapy that Novo stopped developing in October 2025. Under the terms of the deal, Novo will take a stake in Cellular Intelligence's capital and receive future payments for achieving clinical milestones and potentially royalties from sales.

When a large pharmaceutical company "closes" a project, it often means the research has hit a dead end or the cost of development has become disproportionate to potential profit. Transferring the project to a young startup signals that Novo sees residual potential in it, but is not willing to make long-term investments.

AI in cell therapy

Cellular Intelligence specializes in applying machine learning to cell drug development. The company plans to use its AI platform for several key tasks:

• Optimization of stem cell production
• Automatic selection of the most effective cell lines
• Prediction of clinical outcomes based on laboratory data
• Reduction of time and costs for development

The approach differs from the traditional one: instead of years of experiments, the company applies big data analysis and predictive models. This is especially important for cell therapies, where each batch of cells is unique.

Why Parkinson's attracts innovators

The transfer of STEM-PD is part of a trend where large pharmaceutical companies abandon costly projects requiring years of clinical trials. Parkinson's disease is particularly interesting: patients critically lack effective methods, and any breakthrough could significantly improve quality of life.

STEM-PD promised restoration of neurons that produce dopamine and die in Parkinson's disease. Theoretically, this could slow or stop the disease's progression. Novo invested years in development but apparently did not achieve the desired results in late-stage trials.

What this means

For Parkinson's patients, this could give the frozen therapy a second chance. For the investment community, this is yet another confirmation of convergence: AI startups are finding it easier to compete with the R&D divisions of large corporations by using data and algorithms instead of pure trial-and-error in the laboratory.